The Government Medical Officers’ Association (GMOA) has raised serious concerns over ongoing shortages of cancer medications within the state healthcare system. At a media briefing on Friday, September 25, the association highlighted a critical shortfall in patient-specific drugs used for cancer treatment in public hospitals during the first two months of this year.

Dr. Ruwan C Gunasekera, a member of the GMOA Executive Committee, noted that despite recent efforts to address the problem, state hospitals continue to experience significant deficits in essential cancer medicines. According to Dr. Gunasekera, while 31,000 units of injectable cancer drugs have recently been supplied to the National Hospital Supply Line (NHSL), challenges remain in distributing 400 pills intended for provincial hospitals, pointing to continuing logistical and supply issues outside major centers.

The GMOA emphasized the need for coordinated action between the Ministry of Health and other relevant departments to ensure a reliable and sufficient supply of cancer medications. Dr. Gunasekera mentioned ongoing initiatives involving private sector collaboration aimed at bolstering drug availability. However, he expressed frustration over what he described as delays and insufficient progress on the part of government agencies in fully implementing these measures.

The shortages have raised concerns about the potential impact on patient care, given the critical role these medicines play in effective cancer management. The GMOA’s statement underscores the urgency of addressing supply chain weaknesses and calls for increased government oversight to prevent treatment disruptions for cancer patients across the country.